Landscapes / Targets
FLT3
19 drugs act on FLT3, in 41 active trials · Any stage · updated 18 Nov 2026
FollowEvery change as it happens, and a Monday email
Drugs19
| Drug | How it works | Company | Stage
Sources: FDA: the drug development process, ClinicalTrials.gov glossary | Next date
| Details |
|---|---|---|---|---|---|
Tyrosine kinase inhibitor |
Approved | 1 May 2027Phase 1/2 trial completes | |||
| How it works | Blocks a kinase | ||||
| Next date | 1 May 2027 · Phase 1/2 trial completes | ||||
| Also tested for | Acute Myeloid Leukemia, Leukemia and 1 more | ||||
| Open drug page | |||||
Tyrosine kinase inhibitor |
Approved | 31 Jul 2028Phase 1/2 trial completes | |||
| How it works | Blocks a kinase | ||||
| Next date | 31 Jul 2028 · Phase 1/2 trial completes | ||||
| Also tested for | Acute Myeloid Leukemia (AML), Non-small Cell Lung Cancer (NSCLC) and 1 more | ||||
| Open drug page | |||||
Kinase inhibitor |
Approved | — | |||
| How it works | Blocks a kinase | ||||
| Also tested for | Tenosynovial Giant Cell Tumor | ||||
| Open drug page | |||||
— |
Phase 3 | 30 Dec 2026Phase 3 trial completes | |||
| Next date | 30 Dec 2026 · Phase 3 trial completes | ||||
| Also tested for | Esophageal Squamous Cell Carcinoma, Ewing Sarcoma and 1 more | ||||
| Open drug page | |||||
— |
Phase 3 | 1 Jul 2027Phase 3 trial completes | |||
| Next date | 1 Jul 2027 · Phase 3 trial completes | ||||
| Open drug page | |||||
Flonoltinibnot checked |
Tyrosine kinase inhibitor |
Phase 3 | 30 Jul 2027Phase 2 trial completes | ||
| How it works | Blocks a kinase | ||||
| Next date | 30 Jul 2027 · Phase 2 trial completes | ||||
| Also tested for | MF, MF,PMF,PPV-MF,PET-MF and 14 more | ||||
| Open drug page | |||||
Tyrosine kinase inhibitor |
Phase 3 | 29 Nov 2027Phase 2 trial completes | |||
| How it works | Blocks a kinase | ||||
| Next date | 29 Nov 2027 · Phase 2 trial completes | ||||
| Also tested for | Gastrointestinal Neoplasms, Gastrointestinal Stromal Tumor (GIST) and 4 more | ||||
| Open drug page | |||||
Clifutinibnot checked |
Tyrosine kinase inhibitor |
Phase 3 | 30 Nov 2027Phase 3 trial completes | ||
| How it works | Blocks a kinase | ||||
| Next date | 30 Nov 2027 · Phase 3 trial completes | ||||
| Also tested for | Acute Myeloid Leukemia, Adult, Leukemia, Acute Myeloid (AML) | ||||
| Open drug page | |||||
Tyrosine kinase inhibitor |
Phase 1/2 | Nov 2026soonPhase 1/2 trial completes | |||
| How it works | Blocks a kinase | ||||
| Next date | Nov 2026 · Phase 1/2 trial completes | ||||
| Also tested for | Leukemia, Myeloid, Acute, Refractory AML and 3 more | ||||
| Open drug page | |||||
— |
Phase 2 | Dec 2026Phase 2 trial completes | |||
| Next date | Dec 2026 · Phase 2 trial completes | ||||
| Also tested for | Non-Hodgkin Lymphoma, B-cell | ||||
| Open drug page | |||||
— |
Phase 2 | 1 Sep 2027Phase 2 trial completes | |||
| Next date | 1 Sep 2027 · Phase 2 trial completes | ||||
| Also tested for | Acute Myeloid Leukemia | ||||
| Open drug page | |||||
Pacritinibnot checked |
Kinase inhibitor |
Phase 2 | Jul 2028Phase 2 trial completes | ||
| How it works | Blocks a kinase | ||||
| Next date | Jul 2028 · Phase 2 trial completes | ||||
| Also tested for | Leukemia, Myelomonocytic, Chronic | ||||
| Open drug page | |||||
— |
Phase 1/2 | 30 Dec 2029Phase 1/2 trial completes | |||
| Next date | 30 Dec 2029 · Phase 1/2 trial completes | ||||
| Also tested for | Relapsed/Refractory Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS) and 2 more | ||||
| Open drug page | |||||
— |
Phase 1 | Jan 2027Phase 1 trial completes | |||
| Next date | Jan 2027 · Phase 1 trial completes | ||||
| Also tested for | Relapsed/Refractory Acute Myeloid Leukemia (R/R AML) | ||||
| Open drug page | |||||
— |
Phase 1 | 7 Mar 2027Phase 1 trial completes | |||
| Next date | 7 Mar 2027 · Phase 1 trial completes | ||||
| Also tested for | Hepatocellular Carcinoma, Advanced Hepatocellular Carcinoma and 1 more | ||||
| Open drug page | |||||
— |
Phase 1 | Jun 2027Phase 1 trial completes | |||
| Next date | Jun 2027 · Phase 1 trial completes | ||||
| Also tested for | Relapsed and Refractory Acute Myeloid Leukemia (RR-AML) | ||||
| Open drug page | |||||
— |
Phase 1 | — | |||
| Also tested for | Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia and 1 more | ||||
| Open drug page | |||||
— |
Phase 1 | — | |||
| Also tested for | AML/MDS, CD33 Expressing Hematological Malignancies | ||||
| Open drug page | |||||
— |
Phase 1 | — | |||
| Also tested for | AML With Gene Mutations | ||||
| Open drug page | |||||
No drugs match “”.
About this list
- Checked
- 16 of 19 drugs. The other 3 are marked “not checked” in the list. How we check
- Matches
- The mechanism of checked drugs, and drug names, so a drug not checked yet may be missing.
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · openFDA updated 17 Nov 2026